USSTOCK.TODAY
Market Closed
Log in Sign up

Kiora Pharmaceuticals Inc(KPRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

KPRX
KPRX
Kiora Pharmaceuticals Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.82
+0.00 -0.46%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$0.82
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -2.93Insider Own ⓘ 11.64%Shs Outstand ⓘ 4.4MPerf Week ⓘ -38.27%
Market Cap ⓘ 0.00BForward P/E ⓘ -EPS next Y ⓘ 30.48%Insider Trans ⓘ -Shs Float ⓘ 3.9MPerf Month ⓘ -64.91%
Enterprise Value ⓘ -0.01BPEG ⓘ -EPS next Q ⓘ -0.14Inst Own ⓘ 35.58%Short Float ⓘ 1.45%Perf Quarter ⓘ -69.14%
Income ⓘ -0.01BP/S ⓘ 3.63EPS this Y ⓘ 60.23%Inst Trans ⓘ 18.02%Short Ratio ⓘ 1.65Perf Half Y ⓘ -69.37%
Sales ⓘ 0.00BP/B ⓘ 0.24EPS next 5Y ⓘ 33.4%ROA ⓘ -48.87%Short Interest ⓘ 0.06MPerf YTD ⓘ -58.32%
Book/sh ⓘ 3.46P/C ⓘ 0.22EPS past 3/5Y ⓘ 75.03% 65.58%ROE ⓘ -67.7%52W High ⓘ -71.79% ($2.91)Perf Year ⓘ -57.24%
Cash/sh ⓘ 3.68P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -82.76%52W Low ⓘ 5.26% ($0.78)Perf 3Y ⓘ -84.14%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ -18.9%Gross Margin ⓘ 84.19%Volatility(W/M) ⓘ 16.69% 11.85%Perf 5Y ⓘ -99.84%
Dividend TTM ⓘ -EV/Sales ⓘ -12.37Sales Y/Y TTM ⓘ -100%Oper. Margin ⓘ -890.17%ATR (14) ⓘ 0.15Perf 10Y ⓘ -99.99%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 7.91EPS Q/Q ⓘ -4582.26%Profit Margin ⓘ -1276.3%RSI (14) ⓘ 14.97Recom ⓘ 1
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 7.91Sales Q/Q ⓘ -SMA20 ⓘ -46.68% ($1.54)Beta ⓘ 0.01Target Price ⓘ $7
Payout ⓘ -Debt/Eq ⓘ 0.02Earnings ⓘ 2026/11/12SMA50 ⓘ -61.75% ($2.14)Rel Volume ⓘ 0.81Prev Close ⓘ $0.82
Employees ⓘ 13LT Debt/Eq ⓘ 0.01EPS/Sales Surpr. ⓘ 26.32% -SMA200 ⓘ -65.06% ($2.35)Avg Volume(3M) ⓘ 0.03MPrice ⓘ $0.82
IPO ⓘ 2015/2/13Option/Short ⓘ No/YesTrades ⓘ 271Volume ⓘ 27,703Change ⓘ -0.46%
Company
KPRX KPRXKiora Pharmaceuticals Inc | NASD | Biotechnology Deep dive

👁️ Kiora Pharmaceuticals (KPRX) is a clinical-stage biotech focused on retinal diseases. Its lead asset, KIO-301, is a "molecular photoswitch" being developed to restore retinal signal transmission in patients who have lost vision due to inherited and age-related retinal degeneration. The pipeline begins with retinitis pigmentosa (RP) and is planned to expand into indications such as choroideremia and Stargardt disease. A distinguishing feature of the company is its collaboration agreements with global ophthalmology partners, including Théa and Senju.

Quote

Over the past 1 year, on the lower side

72% below its 1-year high.

Now $0.82
52w low$0.7852w high$2.91
52W Range2%
Volume ⓘ 27,703

Traded about as much as usual. That is 81% of its average volume.

B
Overall · fairly good
We judged 7 of the 8 questions below. 3 rate excellent and 2 need caution.
Not applicable: dividends.
ETFs holding this stock 3 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #551 of 598 in the industry

Based on market cap of $4M.

FAQ

FAQ

What kind of company is KPRX?

KPRX belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of KPRX?

The market cap of KPRX is approximately $4M, ranking 5,640 within its sector.

What is the 52-week high and low for KPRX?

KPRX has recorded a 52-week high of $2.91 and a low of $0.78.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels